| Literature DB >> 22525313 |
Klaus Urbahns1, Takeshi Yura, Jang B Gupta, Masaomi Tajimi, Hiroshi Fujishima, Tsutomu Masuda, Noriyuki Yamamoto, Yuka Ikegami, Makiko Marumo, Kayo Yasoshima, Nagahiro Yoshida, Toshiya Moriwaki, David Madge, Fiona Chan, Muneto Mogi.
Abstract
Starting from a naphthol-based lead series with low oral bioavailability, we have identified potent TRPV1 antagonists with oral bioavailability in rats. These compounds emerged from SAR studies aimed at replacing the lead's phenol structure whilst maintaining potency. Compound rac-6a is an orally available TRPV1 antagonist with single-digit nanomolar activity. The enantiomers show a low eudismic ratio at the receptor level.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22525313 DOI： 10.1016/j.bmcl.2012.03.108
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823